Secukinumab dosing optimization in patients with moderate‐to‐severe plaque psoriasis: results from the randomized, open‐label OPTIMISE study-Reference-Cited by-同舟云学术

Secukinumab dosing optimization in patients with moderate‐to‐severe plaque psoriasis: results from the randomized, open‐label OPTIMISE study

Published:2019-09-08 Issue:2 Volume:182 Page:304-315
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Reich K.¹²^ORCID,Puig L.³,Szepietowski J.C.⁴,Paul C.⁵^ORCID,Lacour J.P.⁶,Tsianakas A.⁷,Sieder C.⁸,Rissler M.⁹,Pournara E.⁹,Orsenigo R.¹⁰

Affiliation:

1. Institute for Health Services Research in Dermatology and Nursing University Medical Center Hamburg‐Eppendorf Skinflammation^® Center Hamburg Germany

2. Dermatologikum Berlin Berlin Germany

3. Department of Dermatology Hospital de la Santa Creu i Sant Pau Universitat Autònoma de Barcelona Barcelona Spain

4. Department of Dermatology, Venereology and Allergology Wroclaw Medical University Wroclaw Poland

5. Department of Dermatology Toulouse University and Larrey Hospital Toulouse France

6. Hôpital Archet CHU de Nice Nice France

7. University of Münster Münster Germany

8. Novartis Pharma GmbH Nuremberg Germany

9. Novartis Pharma AG Basel Switzerland

10. Novartis Farma SpA Origgio Italy

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.18143

Reference41 articles.

1. Humira [prescribing information]. North Chicago IL: AbbVie Inc. 2017.

2. Remicade [prescribing information]. Horsham PA: Janssen Biotech Inc. 2017.

3. Siliq [prescribing information]. Bridgewater NJ: Valeant Pharmaceuticals North America LLC 2017.

4. Stelara [prescribing information]. Horsham PA: Janssen Biotech Inc. 2017.

5. Taltz [prescribing information]. Indianapolis IN: Eli Lilly and Company 2017.

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Experiencia en la práctica clínica tras la optimización de la dosis del secukinumab en la psoriasis moderada-severa. Serie retrospectiva de 11 casos;Actas Dermo-Sifiliográficas;2024-09

2. Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis;JAMA Dermatology;2024-07-31

3. Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry;Archives of Dermatological Research;2024-06-08

4. Dose reduction of biologics in patients with plaque psoriasis: a review;Frontiers in Pharmacology;2024-03-28

5. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Moderate-to-Severe Psoriasis;Clinical Pharmacokinetics;2024-01-27